Roche and Genentech speak candidly about their fusion - BioBusiness 2012, London

Oct. 14, 2011 - PRLog -- In light of shrinking product pipelines, decreasing product density and an overall scarcity of financing for early stage innovation, biopharma leaders need to nail the right strategy that will be conducive to successful, long-term innovation and new product creation.

For the first time ever Roche and Genentech speak candidly and off the record of what it took to bring to completion the biggest fusion witnessed by the pharma industry in recent times, and appraise the past two years to provide attendees at this key European bio-partnering conference with an “how to” guide for future mergers and alliances, ensuring that a culture of innovation is maintained.

With countless deal proposals never reaching successful completion, knowing what it takes to achieve cut through is a must. GSK, Celgene, Pfizer and more talk through a complete checklist of what is needed to achieve successful engagement with biopharma, from the initial point of contact through to deal completion.  

About BioBusiness 2012:

BioBusiness 2012 is not about the standard commercial messages that you’ll typically hear at other events and more about panels and unique off-the-record case studies cutting through to the issues/solutions that are going to drive the industry forward, prompting lively and incisive debate amongst industry leaders. 65+ global biopharma leaders will speak at this leading European bio-partnering event and over 250 senior decision makers will talk and do business. There is no better forum to get face to face time with the people that matter.

For more information about BioBusiness 2012 visit www.biobusiness-conference.com, email biobusinesswbr.co.uk or call +44 (0) 207 368 9465

BioBusiness 2012, Radisson Blu, London, 31st Jan – 2 2nd February 2012

# # #

WBR is the world's biggest large-scale conference company and part of the PLS group, one of the world's leading providers of strategic business intelligence with 16 offices worldwide.